Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Pharma Holdings Sees Increased Revenue From Sales Of Generic Version Of Bayer’s Aleve-D

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China Pharma Holdings reported a 39 percent increase in net income to $17.8 million in 2008 due to a 76.6 percent increase in sales of its leading OTC cold and flu product PuSen OK (naprooxen and pseudophedrine), the only generic version in China of Bayer's Aleve-D
Advertisement

Related Content

China Pharma Reports Slightly Higher Q2 Profits, Expects To Launch Generic Version Of AstraZeneca's Crestor In 2010
China Pharma Reports Slightly Higher Q2 Profits, Expects To Launch Generic Version Of AstraZeneca's Crestor In 2010
More Investment In China’s Health Care System Unveiled During NPC;  Is It Time To Ask Who Will Benefit First And Most?
Sinovac Awarded High-Tech Status, Which Brings Lower Taxes And Other Government Benefits
Sinovac Awarded High-Tech Status, Which Brings Lower Taxes And Other Government Benefits
Advertisement
UsernamePublicRestriction

Register

SC071124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel